WINDLAS BIOTECH
WINDLAS · NSE
876.10
-47.30 (-5.12%)
as of 30 Oct 2026 close
Open
920.80
High
921.70
Low
865.50
Prev close
923.40
52w high
1,181.90
07 Sept 2026
52w low
697.40
16 Mar 2026
VWAP
886.60
Delivery %
57.3%
of volume
Volume 55,277 · turnover ₹4.90 Cr · NSE bhavcopy (official close) · history since 16 Aug 2021
- ISIN
- INE0H5O01029
- Series
- EQ
- Listed on NSE
- 16 Aug 2021
- Face value
- ₹5
- F&O
- No
Source: NSE equity master · as of 31 Oct 2026
Daily · NSE EOD
Shareholding · as of 30 Sept 2026
Promoters
63.31%
+0.00 pp QoQ
Public
36.69%
26-06
26-09
Promoter share by quarter · source: NSE shareholding filings (XBRL). DIIs include mutual funds and insurers.
Quarterly results · Standalone · latest 30 Jun 2026
filed 10 Aug 2026, 04:54 pm IST| ₹ crore | Jun 26* |
|---|---|
| Revenue | 248 |
| Other income | 5 |
| Total expenses | 230 |
| Operating margin | 10.8% |
| Finance costs | 2 |
| Depreciation | 7 |
| Profit before tax | 23 |
| Tax | 5 |
| Net profit | 18 |
| Net margin | 7.1% |
| EPS (₹) | 8.46 |
Source and definitions
NSE financial-results filings (XBRL / integrated filing). Figures exactly as filed with NSE in the company's results, converted to ₹ crore from the filing's own rounding. Operating margin = (PBT + finance costs + depreciation − other income) ÷ revenue. Net margin = net profit ÷ revenue. * = unaudited quarter. Consolidated figures are shown when the company files them; otherwise standalone.
Coming next in fundamentals
Arrives in Phase 2. Nothing here is estimated or filled in — we only show data we have.
- P/E, P/B, EV/EBITDA, ROE, ROCE (needs balance sheet + market cap)
- FII / DII / mutual fund split (from shareholding XBRL)
- Peer comparison